Skip to main content
Figure 8 | Molecular Medicine

Figure 8

From: Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier

Figure 8

Effect of a chronic oral treatment with nilvadipine on Aβ burden in Tg APPsw and Tg PS1/APPsw mice. Three-month-old Tg APPsw were fed for 17 months with a powder diet containing 0.03% (weight/weight) of nilvadipine formulation of oral dosage (n = 10) or a placebo (n = 12), whereas 10-month-old Tg PS1/APPsw were fed for 10 months with nilvadipine (n = 8) or a placebo (n = 7). (A) Representative pictures (20 × objective) showing the amount of Aβ deposits in the hippocampus of Tg APPsw and Tg PS1/APPsw following treatment with a placebo or nilvadipine. Histograms representing the amount of Aβ burden in the cortex and hippocampus of Tg APPsw mice (B) and Tg PS1/APPsw mice (C) treated with nilvadipine and the placebo. ANOVA reveals a statistically significant main effect of the nilvadipine treatment in Tg APPsw (P < 0.003) and in Tg PS1/APPsw mice (P < 0.001). Post hoc analyses reveals a statistically significant difference in Aβ burden for the cortex and hippocampus of placebo and nivadipine treated Tg APPsw (P < 0.003) and Tg PS1/APPsw mice (P < 0.001) showing that nilvadipine is reducing Aβ accumulation in the brains of Tg APPsw and Tg PS1/APPsw mice.

Back to article page

Molecular Medicine

ISSN: 1528-3658